Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6689277,Maximum concentrations,"Maximum concentrations of mepindolol in the plasma of 25 ng ml-1 were achieved 1.6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet.",Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),[ng] / [ml],25,1938,DB00960,Pindolol
,6689277,half-life of disposition,"Maximum concentrations of mepindolol in the plasma of 25 ng ml-1 were achieved 1.6 h after both treatments and the half-life of disposition was calculated to be 4-5 h, being somewhat longer after the combination tablet.",Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),h,4-5,1939,DB00960,Pindolol
,6689277,half-life of renal excretion,The half-life of renal excretion was 3 h.,Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6689277/),h,3,1940,DB00960,Pindolol
,25432141,clearance,"Sinistrin clearance as a marker of GFR was significantly elevated (mean, 180 (95% confidence interval (CI), 141 to 219) ml/min) and correlated well with creatinine clearance (r = 0.70, P < 0.01).",Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25432141/),[ml] / [min],180,10060,DB00960,Pindolol
,25432141,Net tubular secretion,"Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min).",Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25432141/),[ml] / [min],428,10061,DB00960,Pindolol
,25432141,net tubular reabsorption,"Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min).",Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25432141/),[ml] / [min],135,10062,DB00960,Pindolol
,6487506,bioavailability,After oral administration no significant differences were observed in bioavailability (59.4 +/- 6.2% in patients vs 79.5 +/- 8.6% in controls) and for most plasma and urinary pharmacokinetic parameters between the experimental and control groups as a whole.,Study of the bioavailability of pindolol in malabsorption syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),%,59.4,14819,DB00960,Pindolol
,6487506,bioavailability,After oral administration no significant differences were observed in bioavailability (59.4 +/- 6.2% in patients vs 79.5 +/- 8.6% in controls) and for most plasma and urinary pharmacokinetic parameters between the experimental and control groups as a whole.,Study of the bioavailability of pindolol in malabsorption syndromes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),%,79.5,14820,DB00960,Pindolol
,6487506,V,"After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/- 0.25 l kg-1 vs 3.05 +/- 0.31 l kg-1) and global elimination constant was larger (ke: 1.43 +/- 0.46 h-1 vs 0.56 +/- 0.10 h-1), in patients with malabsorption than in controls (P less than 0.05).",Study of the bioavailability of pindolol in malabsorption syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),[l] / [kg],2.10,14821,DB00960,Pindolol
,6487506,V,"After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/- 0.25 l kg-1 vs 3.05 +/- 0.31 l kg-1) and global elimination constant was larger (ke: 1.43 +/- 0.46 h-1 vs 0.56 +/- 0.10 h-1), in patients with malabsorption than in controls (P less than 0.05).",Study of the bioavailability of pindolol in malabsorption syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),[l] / [kg],3.05,14822,DB00960,Pindolol
,6487506,ke,"After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/- 0.25 l kg-1 vs 3.05 +/- 0.31 l kg-1) and global elimination constant was larger (ke: 1.43 +/- 0.46 h-1 vs 0.56 +/- 0.10 h-1), in patients with malabsorption than in controls (P less than 0.05).",Study of the bioavailability of pindolol in malabsorption syndromes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),1/[h],1.43,14823,DB00960,Pindolol
,6487506,ke,"After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/- 0.25 l kg-1 vs 3.05 +/- 0.31 l kg-1) and global elimination constant was larger (ke: 1.43 +/- 0.46 h-1 vs 0.56 +/- 0.10 h-1), in patients with malabsorption than in controls (P less than 0.05).",Study of the bioavailability of pindolol in malabsorption syndromes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487506/),1/[h],0.56,14824,DB00960,Pindolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21283,DB00960,Pindolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21284,DB00960,Pindolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21285,DB00960,Pindolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21286,DB00960,Pindolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21287,DB00960,Pindolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21288,DB00960,Pindolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21289,DB00960,Pindolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21290,DB00960,Pindolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,4.4,21291,DB00960,Pindolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,5.9,21292,DB00960,Pindolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.4,21293,DB00960,Pindolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.3,21294,DB00960,Pindolol
,427002,Plasma half time,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),h,2.9,30762,DB00960,Pindolol
,427002,bioavailability,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,53,30763,DB00960,Pindolol
,427002,Plasma protein binding,Plasma protein binding was 38% and was independent of plasma concentration; the drug was not concentrated in the red cell.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,38,30764,DB00960,Pindolol
,8398605,detection limits,The detection limits of 5 ng/ml enantiomer in plasma and 50 ng/ml enantiomer in urine are sufficient for pharmacokinetic studies after therapeutic doses.,"Direct enantiospecific HPLC bioanalysis of (R,S)-atenolol on a chiral stationary phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398605/),[ng] / [ml],5,46431,DB00960,Pindolol
,8398605,detection limits,The detection limits of 5 ng/ml enantiomer in plasma and 50 ng/ml enantiomer in urine are sufficient for pharmacokinetic studies after therapeutic doses.,"Direct enantiospecific HPLC bioanalysis of (R,S)-atenolol on a chiral stationary phase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398605/),[ng] / [ml],50,46432,DB00960,Pindolol
,6148873,half-life,"Twenty-four hours after the dose, the percentage of the maximal heart rate-attenuating effect was highest for nadolol (pharmacokinetic half-life, 15.5 hours), followed by atenolol and then by pindolol (half-life, 5.5 hours).","Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148873/),h,15.5,47871,DB00960,Pindolol
,6148873,half-life,"Twenty-four hours after the dose, the percentage of the maximal heart rate-attenuating effect was highest for nadolol (pharmacokinetic half-life, 15.5 hours), followed by atenolol and then by pindolol (half-life, 5.5 hours).","Atenolol, nadolol, and pindolol in angina pectoris on effort: effect of pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148873/),h,5.5,47872,DB00960,Pindolol
,7333348,t1/2,The apparent half-life of elimination in plasma (t1/2 = 4.05 h) and in urine (t1/2 = 3.21 h) was calculated using conventional pharmacokinetic methods.,Simultaneous tubular excretion and reabsorption of pindolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333348/),h,4.05,47917,DB00960,Pindolol
,7333348,t1/2,The apparent half-life of elimination in plasma (t1/2 = 4.05 h) and in urine (t1/2 = 3.21 h) was calculated using conventional pharmacokinetic methods.,Simultaneous tubular excretion and reabsorption of pindolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333348/),h,3.21,47918,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],119,58961,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],130,58962,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],469,58963,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],467,58964,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],204,58965,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],190,58966,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],225,58967,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],209,58968,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],14.9,58969,DB00960,Pindolol
,11422014,renal clearances,"The renal clearances of sinistrin (M: 119 +/- 31 ml min(-1); M + F: 130 +/- 40 ml min(-1); P = 0.32), PAH (M: 469 +/- 145 ml min(-1); M + F: 467 +/- 146 ml min(-1); P = 0.95), R-pindolol (M: 204 +/- 41 ml min(-1); M + F: 190 +/- 41 ml min(-1); P = 0.39; n = 11), S-pindolol (M: 225 +/- 55 ml min(-1); M + F: 209 +/- 60 ml min(-1); P = 0.27; n = 11) and fluconazole (F: 14.9 +/- 3.8 ml min(-1); M + F: 13.6 +/- 3.4 ml min(-1); P = 0.16) were similar when the markers or fluconazole were administered alone (M or F) or as a cocktail (M + F).","Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422014/),[ml] / [min],13.6,58970,DB00960,Pindolol
,1982762,elimination half-life,"However, the elimination half-life was 6.0 h in controls and 9.5 h in cirrhotics.",Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982762/),h,6.0,69236,DB00960,Pindolol
,1982762,elimination half-life,"However, the elimination half-life was 6.0 h in controls and 9.5 h in cirrhotics.",Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982762/),h,9.5,69237,DB00960,Pindolol
,7222728,elimination half-life,An elimination half-life of 1.5 to 1.9 h was estimated in plasma for unchanged pindolol.,Pindolol: disposition and metabolism in rhesus monkeys after chronic treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222728/),h,1.5 to 1.9,69539,DB00960,Pindolol
,7222728,elimination half-life,A mean elimination half-life of 10h was evaluated in 21 organs.,Pindolol: disposition and metabolism in rhesus monkeys after chronic treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7222728/),h,10,69540,DB00960,Pindolol
,27353348,flow rate,Both LNG and PIN were separated on a Zorbax Eclipse XDB C18 column kept at ambient temperature using as mobile phase a combination of 75% methanol: 25% formic acid 0.1% pH 4.1 at a flow rate of 1.0 mL min-1.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ml] / [min],1.0,71019,DB00960,Pindolol
,27353348,limit of quantification (LOQ),The limit of quantification (LOQ) was found to be 5 ng mL-1 based on 100 µL of plasma.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],5,71020,DB00960,Pindolol
>,27353348,extraction recovery (R%),The extraction recovery (R%) was >83%.,A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),%,83,71021,DB00960,Pindolol
,27353348,maximum concentration (Cmax),"The maximum concentration (Cmax) and the area under the plasma concentration-time curve (AUC0-72) were 927.5 ± 23.9 and 18,285.02 ± 605.76 ng mL-1, respectively.",A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],927.5,71022,DB00960,Pindolol
,27353348,area under the plasma concentration-time curve (AUC0-72),"The maximum concentration (Cmax) and the area under the plasma concentration-time curve (AUC0-72) were 927.5 ± 23.9 and 18,285.02 ± 605.76 ng mL-1, respectively.",A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27353348/),[ng] / [ml],"18,285.02",71023,DB00960,Pindolol
,2868747,half-life,After intravenous administration the half-life for the formation of the hydrolysis product was about 0.3 h.,Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),h,0.3,90052,DB00960,Pindolol
,2868747,half-life,"The elimination of hydrolysed bopindolol from the plasma, determined with a one-compartment model occurred with a half-life of about 4 h.",Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),h,4,90053,DB00960,Pindolol
,2868747,half-life,"There were indications for a longer beta phase of elimination with a half-life of about 8 h, which, owing to the relative insensitivity of the method for concentrations present after more than 24 h, could not be determined exactly.",Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),h,8,90054,DB00960,Pindolol
,2868747,absolute bioavailability,The absolute bioavailability of the active compound is about 70%.,Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),%,70,90055,DB00960,Pindolol
,2868747,maximum effect,"With oral doses the maximum effect was reached after 3 h (-29 beats min-1 after 1 mg, -40 beats min-1 after 4 mg).",Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),[beats] / [min],29,90056,DB00960,Pindolol
,2868747,maximum effect,"With oral doses the maximum effect was reached after 3 h (-29 beats min-1 after 1 mg, -40 beats min-1 after 4 mg).",Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),[beats] / [min],40,90057,DB00960,Pindolol
,2868747,maximum effect,After intravenous administration most of the effect was present after 0.5 h but the maximum effect (-33 beats min-1) was only reached at 3 h.,Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),[beats] / [min],-,90058,DB00960,Pindolol
,2868747,maximum effect,After intravenous administration most of the effect was present after 0.5 h but the maximum effect (-33 beats min-1) was only reached at 3 h.,Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868747/),[beats] / [min],33,90059,DB00960,Pindolol
,2702798,peak concentration,In each subject the peak concentration of d-atenolol was greater than the peak concentration of l-atenolol (mean +/- SD of 420 +/- 81 ng/ml vs 366 +/- 61 ng/ml; p less than 0.05).,The pharmacokinetics of the enantiomers of atenolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ng] / [ml],420,91061,DB00960,Pindolol
,2702798,peak concentration,In each subject the peak concentration of d-atenolol was greater than the peak concentration of l-atenolol (mean +/- SD of 420 +/- 81 ng/ml vs 366 +/- 61 ng/ml; p less than 0.05).,The pharmacokinetics of the enantiomers of atenolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ng] / [ml],366,91062,DB00960,Pindolol
,2702798,renal clearances,"The renal clearances of d- and l-atenolol were not significantly different (109.7 +/- 33.5 ml/min vs 112.5 +/- 36.7 ml/min), probably because the major route of renal elimination is glomerular filtration.",The pharmacokinetics of the enantiomers of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ml] / [min],109.7,91063,DB00960,Pindolol
,2702798,renal clearances,"The renal clearances of d- and l-atenolol were not significantly different (109.7 +/- 33.5 ml/min vs 112.5 +/- 36.7 ml/min), probably because the major route of renal elimination is glomerular filtration.",The pharmacokinetics of the enantiomers of atenolol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),[ml] / [min],112.5,91064,DB00960,Pindolol
,2702798,half-lives,The half-lives of d- and l-atenolol were not significantly different (mean +/- SD of 4.6 +/- 1.1 hours vs 5.2 +/- 0.9 hours).,The pharmacokinetics of the enantiomers of atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),h,4.6,91065,DB00960,Pindolol
,2702798,half-lives,The half-lives of d- and l-atenolol were not significantly different (mean +/- SD of 4.6 +/- 1.1 hours vs 5.2 +/- 0.9 hours).,The pharmacokinetics of the enantiomers of atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702798/),h,5.2,91066,DB00960,Pindolol
,17307403,concentrations,"Amniotic fluid/plasma and milk/plasma concentrations ratios ranged from 0.4 to 4.5 and from 0.6 to 3.7, respectively, for (+)-R-pindolol and from 0.5 to 3.5 and from 1.1 to 2.8, respectively, for (-)-S-pindolol.",Determination of pindolol enantiomers in amniotic fluid and breast milk by high-performance liquid chromatography: applications to pharmacokinetics in pregnant and lactating women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17307403/),,0.4 to 4.5,91158,DB00960,Pindolol
,12125040,AUC(SS)0-12,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[h·ng] / [ml],84.34,93028,DB00960,Pindolol
,12125040,AUC(SS)0-12,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[h·ng] / [ml],95.69,93029,DB00960,Pindolol
,12125040,Cl(R),"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[l] / [h],9.16,93030,DB00960,Pindolol
,12125040,Cl(R),"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[l] / [h],10.85,93031,DB00960,Pindolol
,12125040,Vd/f,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),l,251.38,93032,DB00960,Pindolol
,12125040,Vd/f,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),l,225.17,93033,DB00960,Pindolol
,12125040,Cl/f,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[l] / [h],62.48,93034,DB00960,Pindolol
,12125040,Cl/f,"The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol.",Enantioselectivity in the steady-state pharmacokinetics and transplacental distribution of pindolol at delivery in pregnancy-induced hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12125040/),[l] / [h],55.74,93035,DB00960,Pindolol
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,3.0,108999,DB00960,Pindolol
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,1.2,109000,DB00960,Pindolol
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,less,109001,DB00960,Pindolol
,7102525,half-lives of the excretion,"The half-lives of the excretion of radioactivity were 3.0, 1.2, and less than 100 hours.",Pharmacokinetics of pindolol in humans and several animal species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102525/),h,100,109002,DB00960,Pindolol
,4056049,renal clearance,The renal clearance (mean +/- SD) was 240 +/- 55 ml/min for l-pindolol and 200 +/- 51 ml/min for d-pindolol (P less than 0.01).,Stereoselective renal clearance of pindolol in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056049/),[ml] / [min],240,116804,DB00960,Pindolol
,4056049,renal clearance,The renal clearance (mean +/- SD) was 240 +/- 55 ml/min for l-pindolol and 200 +/- 51 ml/min for d-pindolol (P less than 0.01).,Stereoselective renal clearance of pindolol in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4056049/),[ml] / [min],200,116805,DB00960,Pindolol
,7581866,flow-rate,The separation of R(+)- and S(-)-pindolol was accomplished on a reversed-phase cellulose-based chiral column with a mobile phase of 40:60 (v/v) acetonitrile-0.3 M aqueous sodium perchlorate at a flow-rate of 0.5 ml/min.,High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581866/),[ml] / [min],0.5,118662,DB00960,Pindolol
,7581866,limits of detection,"The limits of detection were 1.2 ng/ml of R(+)- and 4.3 ng/ml of S(-)-pindolol in serum, and 21 ng/ml of R(+)- and 76 ng/ml of S(-)-pindolol in urine.",High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581866/),[ng] / [ml],1.2,118663,DB00960,Pindolol
,7581866,limits of detection,"The limits of detection were 1.2 ng/ml of R(+)- and 4.3 ng/ml of S(-)-pindolol in serum, and 21 ng/ml of R(+)- and 76 ng/ml of S(-)-pindolol in urine.",High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581866/),[ng] / [ml],4.3,118664,DB00960,Pindolol
,7581866,limits of detection,"The limits of detection were 1.2 ng/ml of R(+)- and 4.3 ng/ml of S(-)-pindolol in serum, and 21 ng/ml of R(+)- and 76 ng/ml of S(-)-pindolol in urine.",High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581866/),[ng] / [ml],21,118665,DB00960,Pindolol
,7581866,limits of detection,"The limits of detection were 1.2 ng/ml of R(+)- and 4.3 ng/ml of S(-)-pindolol in serum, and 21 ng/ml of R(+)- and 76 ng/ml of S(-)-pindolol in urine.",High-performance liquid chromatographic analysis of pindolol enantiomers in human serum and urine using a reversed-phase cellulose-based chiral column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7581866/),[ng] / [ml],76,118666,DB00960,Pindolol
,3928505,release rate,The results show a satisfactory overall consistency of the data and indicate a release rate of 4.4 +/- SD 1.7 micrograms/min of bioavailable glyceryl trinitrate during the first hour of application of this transdermal system.,"Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928505/),[μg] / [min],4.4,124450,DB00960,Pindolol
,7295884,peaks of mean concentrations,The peaks of mean concentrations of pindolol were 39.7 ng ml-1 at 1.5 h after administration of 7.5 mg drug in combination with isosorbide dinitrate and 38.0 ng ml-1 at 1 h administration of the drug alone.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),[ng] / [ml],39.7,125256,DB00960,Pindolol
,7295884,peaks of mean concentrations,The peaks of mean concentrations of pindolol were 39.7 ng ml-1 at 1.5 h after administration of 7.5 mg drug in combination with isosorbide dinitrate and 38.0 ng ml-1 at 1 h administration of the drug alone.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),[ng] / [ml],38.0,125257,DB00960,Pindolol
,7295884,half-life,Concentrations of pindolol in plasma declined with a half-life of 3 h.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),h,3,125258,DB00960,Pindolol
,6133729,bioavailability,The bioavailability of low doses was 1-2% in the rat and 40% in the dog.,"Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133729/),%,1-2,127332,DB00960,Pindolol
,6133729,bioavailability,The bioavailability of low doses was 1-2% in the rat and 40% in the dog.,"Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133729/),%,40,127333,DB00960,Pindolol
,6133729,half-lives,Plasma levels of unchanged drug declined biphasically in the dog with half-lives of 8 min and 3 hr.,"Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133729/),min,8,127334,DB00960,Pindolol
,6133729,half-lives,Plasma levels of unchanged drug declined biphasically in the dog with half-lives of 8 min and 3 hr.,"Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133729/),h,3,127335,DB00960,Pindolol
,13958,t1/2 of distribution,The t1/2 of distribution ranges between 5 to 30 minutes.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),min,5 to 30,131024,DB00960,Pindolol
,13958,elimination half-life,The beta-blockers are relatively rapidly eliminated from the body and most of them have an elimination half-life between 2 to 4 hours.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),h,2 to 4,131025,DB00960,Pindolol
,37094,time to peak level,The mean time to peak level of pindolol was 1.9 h and the mean half-life was 4.2 h.,beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37094/),h,1.9,138816,DB00960,Pindolol
,37094,half-life,The mean time to peak level of pindolol was 1.9 h and the mean half-life was 4.2 h.,beta-Adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37094/),h,4.2,138817,DB00960,Pindolol
,3700683,Absorption,"Absorption and elimination half-lives ranged between 0.05 to 0.6 and 1.6 to 7.2 hours, respectively.",Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700683/),h,0.05 to 0.6,148569,DB00960,Pindolol
,3700683,elimination half-lives,"Absorption and elimination half-lives ranged between 0.05 to 0.6 and 1.6 to 7.2 hours, respectively.",Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700683/),h,1.6 to 7.2,148570,DB00960,Pindolol
,6628532,peak concentration,"The mean peak concentration was 30.2 +/- 5.0 ng X ml-1, the mean half-life (t1/2) of the elimination phase was 3.4 +/- 1.1 h, and the total body clearance was 628 +/- 13 ml X min-1.",Pharmacokinetics of pindolol in Kenyan Africans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628532/),[ng] / [ml],30.2,166997,DB00960,Pindolol
,6628532,half-life (t1/2) of the elimination phase,"The mean peak concentration was 30.2 +/- 5.0 ng X ml-1, the mean half-life (t1/2) of the elimination phase was 3.4 +/- 1.1 h, and the total body clearance was 628 +/- 13 ml X min-1.",Pharmacokinetics of pindolol in Kenyan Africans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628532/),h,3.4,166998,DB00960,Pindolol
,6628532,total body clearance,"The mean peak concentration was 30.2 +/- 5.0 ng X ml-1, the mean half-life (t1/2) of the elimination phase was 3.4 +/- 1.1 h, and the total body clearance was 628 +/- 13 ml X min-1.",Pharmacokinetics of pindolol in Kenyan Africans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628532/),[ml] / [min],628,166999,DB00960,Pindolol
,6628532,apparent volume of distribution,The apparent volume of distribution was 3.0 +/- 1.31 X kg-1.,Pharmacokinetics of pindolol in Kenyan Africans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628532/),1/[kg],3.0,167000,DB00960,Pindolol
,7117354,tp,"It was found that the plasma levels following a single dose of 14C-pindolol were similar to those observed in healthy volunteers, but the elimination half-life was slightly increased u tp 11.5 h.",Metabolism of pindolol in patients with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117354/),h,11.5,168429,DB00960,Pindolol
,7117354,steady state plasma concentrations,The observed steady state plasma concentrations of pindolol were twice as high but they are still in the therapeutic range of 10 to 100 ng/ml.,Metabolism of pindolol in patients with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7117354/),[ng] / [ml],10 to 100,168430,DB00960,Pindolol
,2739756,HCl,HCl (28.7 +/- 22.5 ng/ml) was applied.,Stereoselective hemodynamic effects of (R)-and (S)-propranolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2739756/),[ng] / [ml],28.7,176538,DB00960,Pindolol
,639828,plasma elimination half-life,"The plasma elimination half-life was identical after SD (4.7 +/- 0,8h) and MD (4.1 +/- 1.1h).",Single and multiple dose pharmacokinetics of pindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/639828/),h,4.7,185815,DB00960,Pindolol
,639828,plasma elimination half-life,"The plasma elimination half-life was identical after SD (4.7 +/- 0,8h) and MD (4.1 +/- 1.1h).",Single and multiple dose pharmacokinetics of pindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/639828/),h,4.1,185816,DB00960,Pindolol
,17457833,limit of detection,The limit of detection in the MRM mode was found to be 1.25 ng/ml.,Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),[ng] / [ml],1.25,205643,DB00960,Pindolol
,17457833,terminal half-lives,"The terminal half-lives of (+)-(R)-2F109 and (-)-(S)-2F109 were 33.5 and 42.6 min, respectively.",Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),min,33.5,205644,DB00960,Pindolol
,17457833,terminal half-lives,"The terminal half-lives of (+)-(R)-2F109 and (-)-(S)-2F109 were 33.5 and 42.6 min, respectively.",Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),min,42.6,205645,DB00960,Pindolol
,2439812,elimination half-life,"In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h).",Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439812/),h,4 and 8,210689,DB00960,Pindolol
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],234,226210,DB00960,Pindolol
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],344,226211,DB00960,Pindolol
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],209,226212,DB00960,Pindolol
,1563208,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of both R-(+)- and S-(-)-pindolol were significantly (p less than 0.01) increased by cimetidine from 234 +/- 90 (mean +/- SD) to 344 +/- 78 ng/ml.hr for R-(+)-pindolol and from 209 +/- 73 to 288 +/- 69 ng/ml.hr for S-(-)-pindolol.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ng] / [h·ml],288,226213,DB00960,Pindolol
,1563208,renal clearance,The renal clearance of R-(+)-pindolol (170 +/- 55 ml/min) was significantly (p less than 0.05) less than that for S-(-)-pindolol (222 +/- 66 ml/min).,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],170,226214,DB00960,Pindolol
,1563208,renal clearance,The renal clearance of R-(+)-pindolol (170 +/- 55 ml/min) was significantly (p less than 0.05) less than that for S-(-)-pindolol (222 +/- 66 ml/min).,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],222,226215,DB00960,Pindolol
,1563208,renal clearances,Cimetidine significantly (p less than 0.01) reduced the renal clearances of R-(+)-pindolol to 104 +/- 18 ml/min and for S-(-)-pindolol to 155 +/- 38 ml/min.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],104,226216,DB00960,Pindolol
,1563208,renal clearances,Cimetidine significantly (p less than 0.01) reduced the renal clearances of R-(+)-pindolol to 104 +/- 18 ml/min and for S-(-)-pindolol to 155 +/- 38 ml/min.,Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1563208/),[ml] / [min],155,226217,DB00960,Pindolol
,241357,half-life of plasma elimination during beta-phase,"The half-life of plasma elimination during beta-phase was 4.6 +/- 0.7 (p.o.) and 4.7 +/- 0.3 (i.v.) h, respectively.","Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/241357/),h,4.6,227627,DB00960,Pindolol
,241357,half-life of plasma elimination during beta-phase,"The half-life of plasma elimination during beta-phase was 4.6 +/- 0.7 (p.o.) and 4.7 +/- 0.3 (i.v.) h, respectively.","Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/241357/),h,4.7,227628,DB00960,Pindolol
,241357,Absorption,Absorption of the drug was 88.3 +/- 9.6% comparing the areas under the curve.,"Pharmacokinetics of a new beta-adrenoceptor blocking agent, LF 17-895, in man. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/241357/),%,88.3,227629,DB00960,Pindolol
,1978546,plasma half-life,"Nadolol, with a plasma half-life of 15.5 hours, had the most pronounced heart rate-lowering effect 24 hours after the daily dose compared to pindolol, which had a half-life of 5.5 hours.",Beta-blocker duration of action and implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978546/),h,15.5,236741,DB00960,Pindolol
,1978546,half-life,"Nadolol, with a plasma half-life of 15.5 hours, had the most pronounced heart rate-lowering effect 24 hours after the daily dose compared to pindolol, which had a half-life of 5.5 hours.",Beta-blocker duration of action and implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1978546/),h,5.5,236742,DB00960,Pindolol
,11199945,times to sustained response,The median times to sustained response (> or = 50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01).,"Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,19,237298,DB00960,Pindolol
,11199945,times to sustained response,The median times to sustained response (> or = 50% reduction of baseline severity maintained until endpoint) were 19 days for fluoxetine plus pindolol (N = 55) and 29 days for fluoxetine plus placebo (N = 56) (p = 0.01).,"Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,29,237299,DB00960,Pindolol
,11199945,Ki,"Mean values were approximately 26 nM, a concentration higher than the Ki of (-)pindolol for human 5-HT1A autoreceptors (11 nM).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),nM,11,237300,DB00960,Pindolol
,11199945,time to sustained response,"A comparison of the data of all sustained responders (N = 27) in the fluoxetine-plus-placebo group with the first 27 responders in the fluoxetine-plus-pindolol group (of a total of 38) revealed a highly significant difference in the time to sustained response (18 and 10 days, respectively; p = 0.0002).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,18,237301,DB00960,Pindolol
,11199945,time to sustained response,"A comparison of the data of all sustained responders (N = 27) in the fluoxetine-plus-placebo group with the first 27 responders in the fluoxetine-plus-pindolol group (of a total of 38) revealed a highly significant difference in the time to sustained response (18 and 10 days, respectively; p = 0.0002).","Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11199945/),d,10,237302,DB00960,Pindolol
,32562572,Cmax,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[ng] / [ml],403,240553,DB00960,Pindolol
,32562572,Tmax,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),h,2.00,240554,DB00960,Pindolol
,32562572,elimination half-life (t1/2 ),"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),h,2.50,240555,DB00960,Pindolol
,32562572,AUC0-12 h,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[h·ng] / [ml],1366,240556,DB00960,Pindolol
,32562572,AUC0-∞,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[h·ng] / [ml],1580,240557,DB00960,Pindolol
,32562572,CL/F,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],25.3,240558,DB00960,Pindolol
,32562572,CLR,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],2.50,240559,DB00960,Pindolol
,32562572,CLNR,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],22.7,240560,DB00960,Pindolol
,32562572,Vd /F,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),l,82.8,240561,DB00960,Pindolol
,32562572,transplacental transfer,"The transplacental transfer of furosemide was 0.43 (0.10 to 0.73), and the amniotic fluid concentration was 11.0 ng/mL (5.51 to 14.6 ng/mL).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),,0.43,240562,DB00960,Pindolol
,32562572,amniotic fluid concentration,"The transplacental transfer of furosemide was 0.43 (0.10 to 0.73), and the amniotic fluid concentration was 11.0 ng/mL (5.51 to 14.6 ng/mL).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[ng] / [ml],11.0,240563,DB00960,Pindolol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,2 and 4,241317,DB00960,Pindolol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,10-12,241318,DB00960,Pindolol
,25817262,overall recoveries,"The overall recoveries of LE300 and its N-methyl metabolite from mouse sera were in the range 97.9-101.5% with %RSD ranging from 0.98% to 3.63%, which were in line with ICH guidelines.",Selective microemulsion liquid chromatography analysis of dopamine receptor antagonist LE300 and its N-methyl metabolite in mouse sera by using a monolithic silica column. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817262/),%,97.9-101.5,245849,DB00960,Pindolol
,6519149,maximum plasma level,The maximum plasma level of 35 +/- 8 ng/ml was reached after 1.4 +/- 0.5 h.,Pharmacokinetics of mepindolol in patients with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519149/),[ng] / [ml],35,256839,DB00960,Pindolol
,6519149,half-life of disposition,The half-life of disposition was 4.0 +/- 1.5 h.,Pharmacokinetics of mepindolol in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519149/),h,4.0,256840,DB00960,Pindolol
,6519149,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was 237 +/- 84 ng X h/ml.,Pharmacokinetics of mepindolol in patients with chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519149/),[h·ng] / [ml],237,256841,DB00960,Pindolol
